Roche's experimental drug fenebrutinib achieved significant results in a Phase III trial for primary progressive multiple sclerosis (PPMS), reducing the risk of disability progression by 12%. This ...
More than two million Americans will suffer a traumatic brain injury in 2026. TBI is one of the leading causes of death and ...
Cerebral palsy represents one of the clearest opportunities in modern medicine to reduce lifelong disability, control ...
The National on MSN
Could stem cell treatments bring about MS breakthrough?
UAE recently used stem cell therapy for disease for first time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results